Literature DB >> 21977112

Pulmonary hypertension during acute respiratory diseases in infants.

Luiza Bardi-Peti1, Eugen Pascal Ciofu.   

Abstract

OBJECTIVES: The study was undertaken to assess whether previously healthy infants with acute respiratory diseases develop elevated pulmonary artery pressures and to identify which type of disease is associated with pulmonary hypertension.
MATERIAL AND METHODS: We performed 2D and Doppler echocardiography in 137 infants, aged between 1 and 12 month, from November 2007 to December 2009. 75 infants had acute respiratory diseases (49 bronchiolitis, 16 interstitial pneumonia, 3 bronchopneumonia, 6 episodic wheezing, 1 lobar pneumonia) and 62 were in the control group. We excluded children with congenital heart diseases and other conditions associated with pulmonary hypertension. The method of time to peak velocity corrected for heart rate was used to estimate pulmonary arterial pressure (PAP). We analysed 2 age-subgroups: 1-2 months and 2-12 months. A Student's t-test for independent samples was used to compare the mean values of variables. OUTCOMES: Increased mean pulmonary pressures (>25mmHg) were measured in 18 infants with respiratory diseases, with the next distribution: 14 bronchiolitis, 2 bronchopneumonia, 1 episodic wheezing, 1 interstitial pneumonia. The values were categorized as mild-moderate pulmonary hypertension. Mean PAP were significantly increased in subjects with clinically bronchoobstructive disease (bronchiolitis, episodic wheezing, bronchopneumonia) vs. control (p=0.05 in first age-subgroup and<0.001 in second age-subgroup). In infants with bronchoobstructive disease hospitalization was significantly longer in patients with pulmonary hypertension vs. normal PAP (p= 0.04 in first age-subgroup and 0.005 in second age-subgroup). In patients with bronchoobstructive diseases, mean PAPm and PAPs were significantly increased in subjects with a moderate/severe episode of wheezing at admission vs. a mild episode (p=0.02). Mean PAPm and PAPs were increased in subjects with interstitial pneumonia vs. control, but without statistic significance.
CONCLUSION: Echocardiography is a non-invasive investigation, which brings valuable information regarding pulmonary hypertension in infantile acute respiratory pathology. We found increased PAP almost exclusively in bronchoobstructive diseases; the mechanic effect of hyperinflation on pulmonary vessels is probably the dominant mechanism. PHT could be a criterion in establishing the severity of an acute wheezing episode, a prognosis factor and an element of therapeutic guidance.

Entities:  

Keywords:  Doppler echocardiography; acute respiratory diseases; pulmonary hypertension

Year:  2010        PMID: 21977112      PMCID: PMC3150087     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  12 in total

1.  Postnatal circulatory adaptation in healthy term and preterm neonates.

Authors:  N J Evans; L N Archer
Journal:  Arch Dis Child       Date:  1990-01       Impact factor: 3.791

2.  Predicting deterioration in previously healthy infants hospitalized with respiratory syncytial virus infection.

Authors:  A M Brooks; J T McBride; K M McConnochie; M Aviram; C Long; C B Hall
Journal:  Pediatrics       Date:  1999-09       Impact factor: 7.124

3.  Factors affecting use of the Doppler-determined time from flow onset to maximal pulmonary artery velocity for measurement of pulmonary artery pressure in children.

Authors:  G A Serwer; A G Cougle; J M Eckerd; B E Armstrong
Journal:  Am J Cardiol       Date:  1986-08-01       Impact factor: 2.778

4.  Quantifying pulmonary hypertension in ventilated infants with bronchiolitis: a pilot study.

Authors:  D Fitzgerald; G M Davis; C Rohlicek; R Gottesman
Journal:  J Paediatr Child Health       Date:  2001-02       Impact factor: 1.954

5.  Cardiac failure in children with pneumonia in Papua New Guinea.

Authors:  F Shann; D MacGregor; J Richens; J Coakley
Journal:  Pediatr Infect Dis J       Date:  1998-12       Impact factor: 2.129

6.  Right ventricular function in infants, children and adolescents: reference values of the tricuspid annular plane systolic excursion (TAPSE) in 640 healthy patients and calculation of z score values.

Authors:  Martin Koestenberger; William Ravekes; Allen D Everett; Hans Peter Stueger; Bernd Heinzl; Andreas Gamillscheg; Gerhard Cvirn; Arnulf Boysen; Andrea Fandl; Bert Nagel
Journal:  J Am Soc Echocardiogr       Date:  2009-05-07       Impact factor: 5.251

7.  Cardiovascular effects of acute bronchiolitis.

Authors:  N Sreeram; J G Watson; S Hunter
Journal:  Acta Paediatr Scand       Date:  1991-01

8.  Echocardiographic assessment of cardiac function during respiratory syncytial virus infection.

Authors:  E Pahl; S S Gidding
Journal:  Pediatrics       Date:  1988-06       Impact factor: 7.124

9.  Treatment of respiratory failure with inhaled nitric oxide and high- frequency ventilation in an infant with respiratory syncytial virus pneumonia and bronchopulmonary dysplasia.

Authors:  T Hoehn; M Krause; M Krueger; R Hentschel
Journal:  Respiration       Date:  1998       Impact factor: 3.580

10.  Doppler assessment of pulmonary artery pressure and extrapulmonary shunting in the acute phase of hyaline membrane disease.

Authors:  N J Evans; L N Archer
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

View more
  2 in total

1.  New mouse model of pulmonary hypertension induced by respiratory syncytial virus bronchiolitis.

Authors:  Dai Kimura; Jordy Saravia; Sridhar Jaligama; Isabella McNamara; Luan D Vu; Ryan D Sullivan; Salvatore Mancarella; Dahui You; Stephania A Cormier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-15       Impact factor: 4.733

2.  Deficiency in ST2 signaling ameliorates RSV-associated pulmonary hypertension.

Authors:  Luan D Vu; Jordy Saravia; Sridhar Jaligama; Rajshri V Baboeram Panday; Ryan D Sullivan; Salvatore Mancarella; Stephania A Cormier; Dai Kimura
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-06-25       Impact factor: 5.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.